REG - Trellus Health PLC - Result of AGM

Trellus HealthAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250701:nRSA0883Pa&default-theme=true

RNS Number : 0883P  Trellus Health PLC  01 July 2025

Trellus Health plc

("Trellus Health", the "Company" or the "Group")

 

Result of Annual General Meeting

 

The Annual General Meeting of Trellus Health plc was held at Temple Chambers,
3-7 Temple Avenue, London, EC4Y 0DT on 30 June 2025 at 1:00 p.m. (UK time)

 

All 13 resolutions put to members were passed on a poll. Resolutions 1 to 11
were passed as ordinary resolutions and resolutions 12 and 13 were passed as
special resolutions.  The full text of the resolutions passed at the Annual
General Meeting is set out in the Notice of Meeting, which is available on the
Company's website at https://trellushealth.com/investors
(https://trellushealth.com/investors)

 

The number of votes cast for and against each of the resolutions proposed, and
the number of votes withheld were as follows:

 

  Resolution               Votes for   %        Votes against  %       Votes withheld
 Resolution 1 (Ordinary)   27,025,398  99.9999  29             0.0001  643,426

 Resolution 2 (Ordinary)   20,516,614  75.92    6,508,690      24.08   643,549

 Resolution 3 (Ordinary)   26,767,828  99.92    20,253         0.08    880,772

 Resolution 4 (Ordinary)   26,290,923  97.87    571,760        2.13    806,170

 Resolution 5 (Ordinary)   26,766,798  99.64    95,762         0.36    806,293

 Resolution 6 (Ordinary)   26,756,319  99.60    106,364        0.40    806,170

 Resolution 7 (Ordinary)   20,506,319  76.34    6,356,364      23.66   806,170

 Resolution 8 (Ordinary)   19,851,366  73.90    7,011,317      26.10   806,170

 Resolution 9 (Ordinary)   26,942,921  99.69    82,506         0.31    643,426

 Resolution 10 (Ordinary)  26,948,536  99.72    76,891         0.28    643,426

 Resolution 11 (Ordinary)  26,767,808  99.67    89,875         0.33    811,170

 Resolution 12 (Special)   26,756,053  99.71    77,649         0.29    835,151

 Resolution 13 (Special)   26,771,655  99.66    90,905         0.34    806,293

 

The Board notes that Resolutions 2, 7 and 8 received a significant number of
votes against those resolutions. In accordance with the QCA Corporate
Governance Code, the Board remains committed to maintaining an open and
transparent dialogue with shareholders and will continue to consult on any
material issues of concern.

 

As at 30 June 2025, there were 161,508,333 ordinary shares in issue.
Shareholders are entitled to one vote per share. Votes withheld are not votes
in law and so have not been included in the calculation of the proportion of
votes for and against a resolution.

 

The full text of each resolution is available in the Notice of Annual General
Meeting, published on our website.

Enquiries:

 

 Trellus Health plc                                                     https://trellushealth.com/ (https://trellushealth.com/)
 Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder            Via Walbrook PR
 Joy Bessenger, Chief Financial Officer

 Singer Capital Markets
 Jen Boorer / James Todd / Jalini Kalaravy                             Tel: +44 (0)20 7496 3000

 Walbrook PR           Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com
                       (mailto:trellus@walbrookpr.com)
 Paul McManus / Lianne Applegarth /          Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/
 Alice Woodings                                                        +44 (0)7407 804 654

 

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based
innovative solutions and services, helping people with chronic conditions take
control of their health through a proven, scientifically validated
self-management solution and continuous, personalised support. Trellus
Health's approach empowers patients to better navigate the emotional and
physical challenges of their conditions, leading to significant cost savings,
enhanced treatment adherence, and long-term, sustainable health outcomes.

 

Trellus Health integrates its proprietary resilience-based methodology with
the technology, tools, and expert coaching and educator team to deliver
Trellus Elevate®, a whole-person technology-enhanced condition management
platform. The Company is initially focusing on chronic costly GI conditions
that have a high mental health burden, such as Inflammatory Bowel Disease
(IBD). Among IBD patients, applying Trellus Elevate resulted in over 90% fewer
hospitalisations and a reduction of over 70% in emergency room visits. Given
the common emotional and mental health struggles associated with a variety of
chronic conditions, Trellus Health considers its approach to have potential
utility and demand across many conditions.

 

Trellus Health also offers a seamless solution for pharmaceutical partners
from clinical trials to commercialisation, harnessing resilience-based methods
to drive both trial and patient support success by empowering patients to stay
engaged, adhere to their treatment, and manage their health confidently.

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD
and Laurie Keefer, PhD, both world-leading experts at treating and healing
both the physical and emotional impacts of IBD and have been innovators for
whole-person healthcare for a combined 50 years.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS. For more information, visit: www.trellushealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGURSRRVKUNOUR